Eurasian Hematology-Oncology Group

http://www.ehog.net/

 

7th Eurasian Hematology Oncology Summit
E

2020 Updates on CAR-T in R/R MM: What Is the Incidence of AEs With bb2121? Does Idecabtagene Vicleucel Improve ORR? Is Orvacabtagene Autoleucel Safe and Tolerable?

By 7th Eurasian Hematology Oncology Summit FEATURING Evangelos Terpos
By 7th Eurasian Hematology Oncology Summit FEATURING Evangelos Terpos
123 views
December 11, 2020
Comments 0
Login to view comments. Click here to Login

Featured Video

14:18
Incyte

Early Intervention in Chronic GVHD: Evaluating Efficacy and Safety O…

Feat. H. Ali

Featured Video

15:11
Incyte

The Importance of Intervention at the First Signs of Initial Systemi…

Feat. P. Chaudhary
Myeloma
18:43

2020 Updates on CAR-T in R/R MM: What Is the Incidence of AEs With b…

7th Eurasian Hematology Oncology Summit

E. Terpos

123 views
14:20

How I Treat Newly Diagnosed MM in 2020: Is VTD Superior to VCD? Is D…

7th Eurasian Hematology Oncology Summit

A. Maiolino

147 views
16:17

VRd, KRd and IRd in R/R MM: Real World vs. Clinical Trial Data

7th Eurasian Hematology Oncology Summit

A. Chari

492 views
15:49

2020 Updates on Maintenance Therapies in MM: Should We Consider Doub…

7th Eurasian Hematology Oncology Summit

M. Gavriatopoulou

85 views